List of Tables
Table 1. Global Orally Inhaled Generic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Orally Inhaled Generic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Orally Inhaled Generic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Orally Inhaled Generic Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Orally Inhaled Generic Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Orally Inhaled Generic Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Orally Inhaled Generic Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Orally Inhaled Generic Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Orally Inhaled Generic Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Orally Inhaled Generic Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Orally Inhaled Generic Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Orally Inhaled Generic Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Orally Inhaled Generic Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orally Inhaled Generic Drugs as of 2024)
Table 16. Global Orally Inhaled Generic Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Orally Inhaled Generic Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Orally Inhaled Generic Drugs Manufacturing Base and Headquarters
Table 19. Global Orally Inhaled Generic Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Orally Inhaled Generic Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Orally Inhaled Generic Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Orally Inhaled Generic Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Orally Inhaled Generic Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Orally Inhaled Generic Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Orally Inhaled Generic Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Orally Inhaled Generic Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Orally Inhaled Generic Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Orally Inhaled Generic Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Orally Inhaled Generic Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Orally Inhaled Generic Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Orally Inhaled Generic Drugs Growth Accelerators and Market Barriers
Table 37. North America Orally Inhaled Generic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Orally Inhaled Generic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Orally Inhaled Generic Drugs Growth Accelerators and Market Barriers
Table 40. Europe Orally Inhaled Generic Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Orally Inhaled Generic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Orally Inhaled Generic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Orally Inhaled Generic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Orally Inhaled Generic Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Orally Inhaled Generic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Orally Inhaled Generic Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Orally Inhaled Generic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Orally Inhaled Generic Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Orally Inhaled Generic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. GSK Corporation Information
Table 51. GSK Description and Major Businesses
Table 52. GSK Product Models, Descriptions and Specifications
Table 53. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. GSK Sales Value Proportion by Product in 2024
Table 55. GSK Sales Value Proportion by Application in 2024
Table 56. GSK Sales Value Proportion by Geographic Area in 2024
Table 57. GSK Orally Inhaled Generic Drugs SWOT Analysis
Table 58. GSK Recent Developments
Table 59. AstraZeneca Corporation Information
Table 60. AstraZeneca Description and Major Businesses
Table 61. AstraZeneca Product Models, Descriptions and Specifications
Table 62. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. AstraZeneca Sales Value Proportion by Product in 2024
Table 64. AstraZeneca Sales Value Proportion by Application in 2024
Table 65. AstraZeneca Sales Value Proportion by Geographic Area in 2024
Table 66. AstraZeneca Orally Inhaled Generic Drugs SWOT Analysis
Table 67. AstraZeneca Recent Developments
Table 68. Boehringer-Ingelheim Corporation Information
Table 69. Boehringer-Ingelheim Description and Major Businesses
Table 70. Boehringer-Ingelheim Product Models, Descriptions and Specifications
Table 71. Boehringer-Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Boehringer-Ingelheim Sales Value Proportion by Product in 2024
Table 73. Boehringer-Ingelheim Sales Value Proportion by Application in 2024
Table 74. Boehringer-Ingelheim Sales Value Proportion by Geographic Area in 2024
Table 75. Boehringer-Ingelheim Orally Inhaled Generic Drugs SWOT Analysis
Table 76. Boehringer-Ingelheim Recent Developments
Table 77. CTTQ Corporation Information
Table 78. CTTQ Description and Major Businesses
Table 79. CTTQ Product Models, Descriptions and Specifications
Table 80. CTTQ Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. CTTQ Sales Value Proportion by Product in 2024
Table 82. CTTQ Sales Value Proportion by Application in 2024
Table 83. CTTQ Sales Value Proportion by Geographic Area in 2024
Table 84. CTTQ Orally Inhaled Generic Drugs SWOT Analysis
Table 85. CTTQ Recent Developments
Table 86. Sphsine Corporation Information
Table 87. Sphsine Description and Major Businesses
Table 88. Sphsine Product Models, Descriptions and Specifications
Table 89. Sphsine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Sphsine Sales Value Proportion by Product in 2024
Table 91. Sphsine Sales Value Proportion by Application in 2024
Table 92. Sphsine Sales Value Proportion by Geographic Area in 2024
Table 93. Sphsine Orally Inhaled Generic Drugs SWOT Analysis
Table 94. Sphsine Recent Developments
Table 95. Daphne Pharmaceutical Corporation Information
Table 96. Daphne Pharmaceutical Description and Major Businesses
Table 97. Daphne Pharmaceutical Product Models, Descriptions and Specifications
Table 98. Daphne Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Daphne Pharmaceutical Recent Developments
Table 100. Jewim Pharmaceutical Corporation Information
Table 101. Jewim Pharmaceutical Description and Major Businesses
Table 102. Jewim Pharmaceutical Product Models, Descriptions and Specifications
Table 103. Jewim Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Jewim Pharmaceutical Recent Developments
Table 105. CF PharmTech Corporation Information
Table 106. CF PharmTech Description and Major Businesses
Table 107. CF PharmTech Product Models, Descriptions and Specifications
Table 108. CF PharmTech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. CF PharmTech Recent Developments
Table 110. Xianju Pharmaceutical Corporation Information
Table 111. Xianju Pharmaceutical Description and Major Businesses
Table 112. Xianju Pharmaceutical Product Models, Descriptions and Specifications
Table 113. Xianju Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Xianju Pharmaceutical Recent Developments
Table 115. Joincare Pharmaceutical Corporation Information
Table 116. Joincare Pharmaceutical Description and Major Businesses
Table 117. Joincare Pharmaceutical Product Models, Descriptions and Specifications
Table 118. Joincare Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Joincare Pharmaceutical Recent Developments
Table 120. Hengrui Medicine Corporation Information
Table 121. Hengrui Medicine Description and Major Businesses
Table 122. Hengrui Medicine Product Models, Descriptions and Specifications
Table 123. Hengrui Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Hengrui Medicine Recent Developments
Table 125. Purity Pharmaceutical Corporation Information
Table 126. Purity Pharmaceutical Description and Major Businesses
Table 127. Purity Pharmaceutical Product Models, Descriptions and Specifications
Table 128. Purity Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Purity Pharmaceutical Recent Developments
Table 130. Key Raw Materials Distribution
Table 131. Raw Materials Key Suppliers
Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 133. Milestones in Production Technology Evolution
Table 134. Distributors List
Table 135. Market Trends and Market Evolution
Table 136. Market Drivers and Opportunities
Table 137. Market Challenges, Risks, and Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Orally Inhaled Generic Drugs Product Picture
Figure 2. Global Orally Inhaled Generic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. DPI Product Picture
Figure 4. MDI Product Picture
Figure 5. NEB Product Picture
Figure 6. Global Orally Inhaled Generic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Asthma
Figure 8. COPD
Figure 9. Inhalation Anesthesia
Figure 10. Others
Figure 11. Orally Inhaled Generic Drugs Report Years Considered
Figure 12. Global Orally Inhaled Generic Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 14. Global Orally Inhaled Generic Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Orally Inhaled Generic Drugs Revenue Market Share by Region (2020-2031)
Figure 16. Global Orally Inhaled Generic Drugs Sales (2020-2031) & (K Units)
Figure 17. Global Orally Inhaled Generic Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Orally Inhaled Generic Drugs Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Orally Inhaled Generic Drugs Sales Volume Market Share in 2024
Figure 20. Global Orally Inhaled Generic Drugs Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. DPI Revenue Market Share by Manufacturer in 2024
Figure 23. MDI Revenue Market Share by Manufacturer in 2024
Figure 24. NEB Revenue Market Share by Manufacturer in 2024
Figure 25. Global Orally Inhaled Generic Drugs Sales Market Share by Type (2020-2031)
Figure 26. Global Orally Inhaled Generic Drugs Revenue Market Share by Type (2020-2031)
Figure 27. Global Orally Inhaled Generic Drugs Sales Market Share by Application (2020-2031)
Figure 28. Global Orally Inhaled Generic Drugs Revenue Market Share by Application (2020-2031)
Figure 29. North America Orally Inhaled Generic Drugs Sales YoY (2020-2031) & (K Units)
Figure 30. North America Orally Inhaled Generic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 31. North America Top 5 Manufacturers Orally Inhaled Generic Drugs Sales Revenue (US$ Million) in 2024
Figure 32. North America Orally Inhaled Generic Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 33. North America Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 34. North America Orally Inhaled Generic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 35. North America Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 36. US Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Canada Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Mexico Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Europe Orally Inhaled Generic Drugs Sales YoY (2020-2031) & (K Units)
Figure 40. Europe Orally Inhaled Generic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Europe Top 5 Manufacturers Orally Inhaled Generic Drugs Sales Revenue (US$ Million) in 2024
Figure 42. Europe Orally Inhaled Generic Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 43. Europe Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 44. Europe Orally Inhaled Generic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 45. Europe Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. Germany Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. France Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. U.K. Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Italy Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Russia Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Orally Inhaled Generic Drugs Sales YoY (2020-2031) & (K Units)
Figure 52. Asia-Pacific Orally Inhaled Generic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Top 8 Manufacturers Orally Inhaled Generic Drugs Sales Revenue (US$ Million) in 2024
Figure 54. Asia-Pacific Orally Inhaled Generic Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 55. Asia-Pacific Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 56. Asia-Pacific Orally Inhaled Generic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 57. Asia-Pacific Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 58. Indonesia Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. Japan Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. South Korea Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. China Taiwan Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. India Orally Inhaled Generic Drugs Revenue (2020-2031) & (US$ Million)
Figure 63. Central and South America Orally Inhaled Generic Drugs Sales YoY (2020-2031) & (K Units)
Figure 64. Central and South America Orally Inhaled Generic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Central and South America Top 5 Manufacturers Orally Inhaled Generic Drugs Sales Revenue (US$ Million) in 2024
Figure 66. Central and South America Orally Inhaled Generic Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 67. Central and South America Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 68. Central and South America Orally Inhaled Generic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 69. Central and South America Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 70. Brazil Orally Inhaled Generic Drugs Revenue (2020-2025) & (US$ Million)
Figure 71. Argentina Orally Inhaled Generic Drugs Revenue (2020-2025) & (US$ Million)
Figure 72. Middle East, and Africa Orally Inhaled Generic Drugs Sales YoY (2020-2031) & (K Units)
Figure 73. Middle East and Africa Orally Inhaled Generic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Middle East and Africa Top 5 Manufacturers Orally Inhaled Generic Drugs Sales Revenue (US$ Million) in 2024
Figure 75. Middle East and Africa Orally Inhaled Generic Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 76. South America Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Middle East and Africa Orally Inhaled Generic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 78. Middle East and Africa Orally Inhaled Generic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. GCC Countries Orally Inhaled Generic Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. Turkey Orally Inhaled Generic Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. Egypt Orally Inhaled Generic Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. South Africa Orally Inhaled Generic Drugs Revenue (2020-2025) & (US$ Million)
Figure 83. Orally Inhaled Generic Drugs Industry Chain Mapping
Figure 84. Regional Orally Inhaled Generic Drugs Manufacturing Base Distribution (%)
Figure 85. Global Orally Inhaled Generic Drugs Production Market Share by Region (2020-2031)
Figure 86. Orally Inhaled Generic Drugs Production Process
Figure 87. Regional Orally Inhaled Generic Drugs Production Cost Structure
Figure 88. Channels of Distribution (Direct Vs Distribution)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
